MCID: PPT001
MIFTS: 52

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 17 71
Reflux Esophagitis 12 74 15
Gastro-Esophageal Reflux Disease with Esophagitis 71
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 34 530.11
MeSH 44 D004942
SNOMED-CT 67 57643001
UMLS 71 C0014869 C0677659

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to esophagitis, eosinophilic, 1 and gastrointestinal ulceration, recurrent, with dysfunctional platelets. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Human cytomegalovirus infection and Toll-Like receptor Signaling Pathways. The drugs Trimebutine and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include colon, smooth muscle and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Wikipedia : 74 Gastroesophageal reflux disease (GERD), is a chronic condition in which stomach contents rise up into... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 707)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 30.9 CCL26 ATP4A ATP12A
2 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.7 S100A8 PTGS2 HRH2 GAST
3 duodenogastric reflux 30.6 MLN GAST ATP4A ATP12A
4 gastrojejunal ulcer 30.5 PTGS2 ATP4A ATP12A
5 gastric dilatation 30.5 ATP4A ATP12A
6 cascade stomach 30.4 HRH2 ATP4A ATP12A
7 superior mesenteric artery syndrome 30.4 HRH2 ATP4A ATP12A
8 pernicious anemia 30.3 GAST ATP4A ATP12A
9 esophageal varix 30.3 ATP4A ATP12A ALB
10 microinvasive gastric cancer 30.2 S100A8 GAST CDX2 ATP4A ATP12A
11 postcholecystectomy syndrome 30.2 MLN GAST
12 hernia, hiatus 30.2 MLN LCT LAT2 HRH2 GAST CYP2C19
13 postgastrectomy syndrome 30.2 MLN GAST ATP12A
14 zollinger-ellison syndrome 30.1 MLN HRH2 GAST ATP4A ATP12A
15 gastroduodenitis 30.0 GAST CCL26 ATP4A ATP12A
16 esophageal candidiasis 30.0 CYP2C19 CCL26 ATP4A ATP12A
17 esophagitis 29.9 TNF PTGS2 IL6 IL1B HRH2 GAST
18 ascaris lumbricoides infection 29.9 IL6 IL1B CXCL8
19 esophagus adenocarcinoma 29.8 PTGS2 CDX2 ATP4A ATP12A
20 helicobacter pylori infection 29.8 TNF IL1B CYP2C19 CXCL8
21 duodenum disease 29.8 S100A8 GAST CDX2 ATP4A ATP12A
22 volvulus of midgut 29.7 MLN ATP4A ATP12A ALB
23 autonomic neuropathy 29.7 MLN GAST ALB
24 dyskinesia of esophagus 29.7 MLN HRH2 CCL26 ATP4A ATP12A
25 bronchiectasis 29.7 TNF IL6 IL1B CXCL8
26 varicose veins 29.7 TNF IL6 CXCL8
27 gastric adenocarcinoma 29.6 S100A8 PTGS2 GAST CDX2
28 fatty liver disease 29.6 TNF IL6 IL1B CXCL8
29 esophageal disease 29.6 CCL26 ATP4A ATP12A ALB
30 acute pancreatitis 29.5 TNF IL6 IL1B CXCL8
31 hepatitis a 29.5 TNF IL1B ALB
32 systemic scleroderma 29.5 TNF MLN IL6 HRH2 GAST
33 candidiasis 29.5 TNF IL6 IL1B CXCL8
34 tropical sprue 29.5 LCT GAST ATP4A ATP12A ALB
35 dermatitis 29.5 TNF IL6 IL1B CXCL8
36 tonsillitis 29.5 TNF IL6 IL1B CXCL8
37 irritable bowel syndrome 29.5 TNF MLN IL6 IL1B CXCL8
38 laryngitis 29.4 TNF IL6 IL1B HRH2 ATP4A ATP12A
39 food allergy 29.4 TNF CXCL8 ALB
40 barrett esophagus 29.4 S100A8 PTGS2 GAST CDX2 ATP4A ATP12A
41 portal hypertension 29.4 TNF CXCL8 ALB
42 glossitis 29.4 TNF IL6 IL1B ATP4A ATP12A
43 urticaria 29.3 TNF PTGS2 IL6 HRH2
44 cystitis 29.3 TNF PTGS2 IL6 CXCL8
45 pharyngitis 29.3 TNF PTGS2 IL6 IL1B CXCL8
46 periodontitis 29.3 TNF PTGS2 IL6 IL1B CXCL8
47 atrophic gastritis 29.3 TNF S100A8 PTGS2 IL6 IL1B GAST
48 pulmonary disease, chronic obstructive 29.2 TNF IL6 IL1B CXCL8 ALB
49 bile reflux 29.2 S100A8 PTGS2 MLN GAST CDX2 ATP4A
50 liver disease 29.1 TNF IL6 IL1B CXCL8 ALB

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Deficiency Anemia Esophageal Disease
Esophagitis Gastroesophageal Reflux
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

MGI Mouse Phenotypes related to Peptic Esophagitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.61 ALB ATP12A ATP4A CDX2 GAST HRH2
2 neoplasm MP:0002006 9.23 ALB ATP4A CDX2 GAST IL1B IL6

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimebutine Approved Phase 4 39133-31-8
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
4
Rebamipide Approved, Investigational Phase 4 90098-04-7
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Calcium polycarbophil Approved Phase 4 126040-58-2
8
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
9
Zinc Approved, Investigational Phase 4 7440-66-6 32051
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Maleic acid Experimental Phase 4 110-16-7 444266
12 Mosapride Investigational Phase 4 112885-41-3
13
Polaprezinc Experimental Phase 4 107667-60-7
14 Indobufen Investigational Phase 4 63610-08-2
15 Parasympatholytics Phase 4
16 Neurotransmitter Agents Phase 4
17 Antioxidants Phase 4
18 Dopamine Agents Phase 4
19 Dopamine Antagonists Phase 4
20 Antiemetics Phase 4
21 Serotonin Receptor Agonists Phase 4
22 Cathartics Phase 4
23 Psyllium Phase 4
24 Laxatives Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Fibrinolytic Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Analgesics Phase 4
30 Antirheumatic Agents Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Platelet Aggregation Inhibitors Phase 4
33 Antipyretics Phase 4
34
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
35
Famotidine Approved Phase 3 76824-35-6 3325
36
Rabeprazole Approved, Investigational Phase 3 117976-89-3 5029
37
Sodium citrate Approved, Investigational Phase 3 68-04-2
38
tannic acid Approved Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
41
Nizatidine Approved Phase 3 76963-41-2 3033637
42
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
44
Lafutidine Investigational Phase 3 118288-08-7 5282136
45 Histamine H2 Antagonists Phase 3
46 Citrate Phase 3
47
Bismuth Phase 3 7440-69-9 16682734 105143
48 Bismuth tripotassium dicitrate Phase 3
49 Ranitidine bismuth citrate Phase 3
50 Respiratory System Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 282)
# Name Status NCT ID Phase Drugs
1 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
2 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
3 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
4 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
5 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
6 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
7 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
8 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
9 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
10 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
11 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
12 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
13 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
14 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
15 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
16 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
17 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
18 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
19 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
20 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
21 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
22 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
25 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
26 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
27 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
28 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
29 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
30 Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial Completed NCT02907632 Phase 4 Metoclopramide;Placebo
31 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Recruiting NCT03467438 Phase 4 Zinc-l-carnosine
32 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Not yet recruiting NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
33 The Effect of Dexilant Treatment on Esophageal Hypersensitivity in GERD Related Non Cardiac Chest Pain Patients Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
34 A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients Unknown status NCT00480285 Phase 3
35 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed NCT00229424 Phase 3 Lafutidine;Famotidine
36 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis Completed NCT00770913 Phase 2, Phase 3 E3810;E3810;E3810
37 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
38 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
39 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of D961H 20 mg Twice Daily Oral Administration and D961H 20 mg Once Daily Oral Administration in Patients With Refractory Reflux Esophagitis Completed NCT01669811 Phase 3 Esomeprazole (D961H) twice daily;Esomeprazole (D961H) once daily
40 Omeprazole Versus Anti-reflux Surgery in the Long-term Management of Peptic Esophagitis - a 10 Year Follow up Study of Patients Previously Studied for 5 Years - A Nordic Multicentre Study Completed NCT00256737 Phase 3 Omeprazole
41 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors Completed NCT03561883 Phase 3 IW-3718;placebo
42 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD. Completed NCT00365300 Phase 3 pantoprazole;Placebo
43 A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux Completed NCT00324974 Phase 3 Lansoprazole microgranules suspension;Placebo
44 A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD) Completed NCT00300755 Phase 3 pantoprazole sodium enteric-coated spheroid
45 A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis Completed NCT00251719 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR;Lansoprazole
46 Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Completed NCT00171418 Phase 3 Tegaserod
47 The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
48 Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD) Completed NCT00734747 Phase 3
49 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients Completed NCT02135107 Phase 3 Rabeprazole;Rabeprazole;Rabeprazole;Rabeprazole
50 Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China Completed NCT02860624 Phase 3 10 mg ilaprazole;40mg esomeprazole

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Calcium Glycerophosphate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
Magnesium Hydroxide
MILK OF MAGNESIA
Nizatidine

Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

40
Colon, Smooth Muscle, Lymph Node, Small Intestine, Tongue, Pancreas, Endothelial

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 3695)
# Title Authors PMID Year
1
Sudden Appearance of Widespread Esophageal Squamous Papilloma With Reflux Esophagitis. 61
32036041 2021
2
[Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm]. 61
33508923 2021
3
The Impact of Erosive Reflux Esophagitis on the Decline of Lung Function in the General Population. 61
33527781 2021
4
A novel method for π-shaped esophagojejunostomy and double-tract reconstruction (DTR) as an alternative in totally laparoscopic or robotic proximal gastrectomy for treating upper third proximal early gastric cancer. 61
33576931 2021
5
Severe Upper Gastrointestinal Hemorrhage Caused by Reflux Esophagitis. 61
33590404 2021
6
Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients. 61
33590389 2021
7
Extra-esophageal symptoms in individuals with and without erosive esophagitis: a case-control study in Albania. 61
33593300 2021
8
Efficacy of vonoprazan for refractory reflux esophagitis after esophagectomy. 61
33567428 2021
9
The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis. 61
32863366 2021
10
Comparative analysis of laparoscopic proximal gastrectomy plus semi-embedded valve anastomosis with laparoscopic total gastrectomy for adenocarcinoma of the esophagogastric junction: a single-center retrospective cohort study. 61
33588854 2021
11
Comparison of 5-year postoperative outcomes after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: Results from a multi-institutional randomized controlled trial. 61
33532685 2021
12
Esophagitis in Cats and Dogs. 61
33187619 2021
13
The Spectrum of Helicobacter-Mediated Diseases. 61
33197219 2021
14
Treatment strategy for laparoscopic hiatal hernia repair. 61
33472278 2021
15
Factors affecting the treatment outcomes of laparoscopic fundoplication for erosive reflux esophagitis: findings of esophageal pathological function tests. 61
33491102 2021
16
Protective Effects of Inflammation of Curcumae Longae Rhizoma 30% EtOH Extract on Acute Reflux Esophagitis Rats. 61
33532497 2021
17
Inhibitory effects of Camellia japonica on cell inflammation and acute rat reflux esophagitis. 61
33413538 2021
18
Clinical features and therapeutic responses to proton pump inhibitor in patients with severe reflux esophagitis: A multicenter prospective observational study. 61
33490619 2021
19
Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients. 61
32860581 2021
20
Feasibility and quality of life assessment of laparoscopic proximal gastrectomy using double-tract reconstruction. 61
33452650 2021
21
Peroral endoscopic myotomy for patients with achalasia with previous Heller myotomy: a systematic review and meta-analysis. 61
32522483 2021
22
Development and Validation of an Automatic Image-Recognition Endoscopic Report Generation System: A Multicenter Study. 61
33395075 2020
23
[Comparison of different reconstruction procedures after distal gastrectomy in patients with gastric cancer]. 61
33371636 2020
24
Inverse time trends of peptic ulcer and reflux esophagitis show significant association with reduced prevalence of Helicobacter pylori infection. 61
32536216 2020
25
Size-dependent differences in the proximal remnant stomach: how much does a small remnant stomach after subtotal gastrectomy work? 61
31950274 2020
26
Effects of Chaihu-Shugan-San for reflux esophagitis: A protocol for systematic review and meta-analysis. 61
33285744 2020
27
CD8 T-Cell-Predominant Lymphocytic Esophagitis is One of the Major Patterns of Lymphocytic Inflammation in Gastroesophageal Reflux Disease. 61
33373450 2020
28
Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life After Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma. 61
33421979 2020
29
Chronic atrophic gastritis and Helicobacter pylori infection status in liver transplant recipients. 61
33207018 2020
30
[Efficacy and safety of pylorus-preserving gastrectomy for early gastric cancer located in the middle third of the stomach: a meta-analysis]. 61
33212558 2020
31
The Usefulness of the Measurement of Esophagogastric Junction Distensibility by EndoFLIP in the Diagnosis of Gastroesophageal Reflux Disease. 61
33115968 2020
32
Trends in gastroesophageal reflux disease in Japanese children and adolescents. 61
32473087 2020
33
Relationship Between Gastroesophageal Reflux Disease and Endoscopic Finding "Iodine-Unstained Streak". 61
33224371 2020
34
Clinical outcomes of laparoscopic and endoscopic cooperative surgery for submucosal tumors on the esophagogastric junction: a retrospective single-center analysis. 61
32476110 2020
35
Proximal gastrectomy with anti-reflux anastomosis for patients with adenocarcinoma of the esophagogastric junction: The simple and safe triangle-valve technique. 61
32963781 2020
36
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer. 61
33118118 2020
37
Helicobacter pylori Infection and Serum Pepsinogen Level With the Risk of Gastric Precancerous Conditions: A Cross-sectional Study of High-risk Gastric Cancer Population in China. 61
33116065 2020
38
Time trends of causes of upper gastrointestinal bleeding and endoscopic findings. 61
33078720 2020
39
Urinary exposure of N-nitrosamines and associated risk of esophageal cancer in a high incidence area in China. 61
32526409 2020
40
Exploration of the characteristics of chronotypes in upper gastrointestinal tract diseases: a multicenter study in Japan. 61
33059467 2020
41
Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy. 61
33130189 2020
42
Predictors of dental erosions in patients evaluated with upper digestive endoscopy: a cross-sectional study. 61
32152820 2020
43
Linked color imaging improves visibility of reflux esophagitis. 61
33109095 2020
44
Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. 61
33074906 2020
45
Comparison of Needlescopic and Conventional Laparoscopic Fundoplication for Gastroesophageal Reflux Disease-Related Diseases: A Propensity Score-Matched Analysis. 61
33124946 2020
46
Interleukin-1A and interleukin-1B gene polymorphisms in gastroesophageal reflux disease. 61
32904982 2020
47
[Current status of anti-reflux surgery of proximal gastrectomy for esophagogastric junction tumor]. 61
33054002 2020
48
Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. 61
32154936 2020
49
Safety and efficacy of peroral endoscopic myotomy with standard myotomy versus short myotomy for treatment-naïve patients with type II achalasia: a prospective randomized trial. 61
33058884 2020
50
[Study of etiology and esophageal motility characteristics of esophagogastric junction outlet obstruction patients]. 61
33047715 2020

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 TNF PTGS2 IL6 IL1B CXCL8
2
Show member pathways
12.68 TNF PTGS2 IL6 IL1B CXCL8
3
Show member pathways
12.29 TNF IL6 CXCL8 CCL26
4
Show member pathways
12.25 TNF PTGS2 IL6 IL1B CXCL8
5
Show member pathways
12.25 TNF PTGS2 IL6 IL1B ALB
6 12.21 TNF IL6 IL1B CXCL8
7
Show member pathways
12.18 TNF PTGS2 IL6 IL1B
8
Show member pathways
12.15 TNF IL6 IL1B CXCL8
9 12.14 TNF IL6 IL1B CXCL8
10
Show member pathways
12.07 TNF S100A8 PTGS2 IL6 IL1B CXCL8
11 12.05 TNF IL6 IL1B CXCL8
12 11.93 TNF PTGS2 IL6 IL1B
13 11.89 TNF PTGS2 IL1B CXCL8
14 11.88 TNF IL6 IL1B CXCL8
15 11.88 TNF PTGS2 IL6 IL1B CXCL8
16 11.85 TNF IL6 IL1B
17 11.85 TNF IL6 IL1B CXCL8
18 11.82 TNF PTGS2 IL6 IL1B CXCL8
19 11.81 TNF IL6 IL1B CXCL8
20
Show member pathways
11.72 TNF IL6 IL1B
21
Show member pathways
11.72 TNF PTGS2 CXCL8
22 11.7 TNF IL6 IL1B
23 11.69 TNF IL6 IL1B CXCL8
24 11.6 TNF IL6 IL1B CXCL8
25 11.53 PTGS2 IL6 CXCL8
26 11.53 TNF IL6 IL1B CXCL8
27 11.46 TNF IL6 IL1B CXCL8
28 11.39 TNF IL6 IL1B CDX2
29 11.37 TNF IL6 IL1B
30 11.33 TNF IL6 IL1B
31 11.29 TNF IL6 IL1B
32 11.27 TNF IL6 IL1B
33 11.23 TNF IL6 IL1B
34
Show member pathways
11.15 TNF PTGS2 IL6 IL1B CXCL8
35 10.97 TNF IL6 IL1B CXCL8 CCL26
36 10.75 IL6 IL1B
37 10.74 TNF PTGS2 IL6 CXCL8
38 10.71 TNF PTGS2 IL6 IL1B CXCL8
39 10.2 HRH2 GAST ATP4A

GO Terms for Peptic Esophagitis

Cellular components related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF S100A8 MLN IL6 IL1B GAST
2 extracellular space GO:0005615 9.28 TNF S100A8 IL6 IL1B GAST CXCL8

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.85 TNF PTGS2 IL6 IL1B CXCL8
2 immune response GO:0006955 9.85 TNF IL6 IL1B HRH2 CXCL8 CCL26
3 cellular response to lipopolysaccharide GO:0071222 9.84 TNF IL6 IL1B CXCL8
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF S100A8 IL6 IL1B
5 positive regulation of inflammatory response GO:0050729 9.81 TNF S100A8 IL1B
6 regulation of inflammatory response GO:0050727 9.8 TNF S100A8 PTGS2
7 positive regulation of interleukin-6 production GO:0032755 9.8 TNF IL6 IL1B
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 TNF PTGS2 IL6
9 neutrophil chemotaxis GO:0030593 9.77 S100A8 CXCL8 CCL26
10 regulation of insulin secretion GO:0050796 9.76 TNF IL6 IL1B
11 response to glucocorticoid GO:0051384 9.75 TNF PTGS2 IL6
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 TNF PTGS2 IL6
13 positive regulation of interleukin-8 production GO:0032757 9.72 TNF IL6 IL1B
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 TNF PTGS2 IL1B
15 sodium ion export across plasma membrane GO:0036376 9.65 ATP4A ATP12A
16 cellular potassium ion homeostasis GO:0030007 9.64 ATP4A ATP12A
17 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.64 ATP4A ATP12A
18 regulation of neuroinflammatory response GO:0150077 9.61 PTGS2 IL6
19 regulation of establishment of endothelial barrier GO:1903140 9.61 TNF IL1B
20 positive regulation of vascular endothelial growth factor production GO:0010575 9.61 PTGS2 IL6 IL1B
21 negative regulation of lipid storage GO:0010888 9.59 TNF IL6
22 negative regulation of neurogenesis GO:0050768 9.58 TNF IL6 IL1B
23 positive regulation of prostaglandin biosynthetic process GO:0031394 9.57 PTGS2 IL1B
24 positive regulation of glial cell proliferation GO:0060252 9.5 TNF IL6 IL1B
25 sequestering of triglyceride GO:0030730 9.49 TNF IL1B
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IL1B
27 positive regulation of neuroinflammatory response GO:0150078 9.43 TNF IL6 IL1B
28 vascular endothelial growth factor production GO:0010573 9.33 TNF IL6 IL1B
29 inflammatory response GO:0006954 9.17 TNF S100A8 PTGS2 IL6 IL1B CXCL8
30 positive regulation of fever generation GO:0031622 9.13 TNF PTGS2 IL1B

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
2 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
3 cytokine activity GO:0005125 9.02 TNF IL6 IL1B CXCL8 CCL26
4 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....